FMR LLC - 19 Sep 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Reporting relationship: Other*
Issuer ticker: NMRA
Reported as of: 19 Sep 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Sep 2023, 08:30:19 UTC
Prior SEC filing: 14 Sep 2023
Next SEC filing: 12 Oct 2023
Source filing: View source filing
Reporting owner signature: Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson

Key filing fact

FMR LLC filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 21 Sep 2023.

Key facts

This page summarizes FMR LLC's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
8 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 21 Sep 2023, 08:30.

Change

Previous filing in this sequence was filed on 14 Sep 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NMRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +3,475,646
Change %: +182%
Price
Shares after: 5,387,375
Date: 19 Sep 2023
Ownership: F-Prime Capital Partners Life Sciences Fund VII LP
Footnotes: F1

NMRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +84,965
Change %: +1.6%
Price
Shares after: 5,472,340
Date: 19 Sep 2023
Ownership: F-Prime Capital Partners Life Sciences Fund VII LP
Footnotes: F1

NMRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +63,724
Change %
Price
Shares after: 63,724
Date: 19 Sep 2023
Ownership: F-Prime Inc.
Footnotes: F1

NMRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +88,289
Change %
Price
Shares after: 88,289
Date: 19 Sep 2023
Ownership: FBRI LLC
Footnotes: F1

NMRA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,911,729
Date: 19 Sep 2023
Ownership: F-Prime Capital Partners Life Sciences Fund VII LP

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NMRA transaction Derivative

Series A-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -63,724
Change %: -100%
Price
Shares after: 0
Date: 19 Sep 2023
Ownership: F-Prime Inc.
Underlying class: Common Stock
Underlying amount: 63,724
Exercise price
Footnotes: F1

NMRA transaction Derivative

Series A-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -3,475,646
Change %: -100%
Price
Shares after: 0
Date: 19 Sep 2023
Ownership: F-Prime Capital Partners Life Sciences Fund VII LP
Underlying class: Common Stock
Underlying amount: 3,475,646
Exercise price
Footnotes: F1

NMRA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -84,965
Change %: -100%
Price
Shares after: 0
Date: 19 Sep 2023
Ownership: F-Prime Capital Partners Life Sciences Fund VII LP
Underlying class: Common Stock
Underlying amount: 84,965
Exercise price
Footnotes: F1

NMRA transaction Derivative

Series A-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -88,289
Change %: -100%
Price
Shares after: 0
Date: 19 Sep 2023
Ownership: FBRI LLC
Underlying class: Common Stock
Underlying amount: 88,289
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

FMR LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC remarks

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: FBRI LLC and F-Prime Inc are wholly-owned subsidiaries of FMR LLC. F-Prime Capital Partners Life Sciences Advisors Fund VII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.